Dr. Anthony on the Pathology of Neuroendocrine Tumors

Lowell Anthony, MD
Published: Wednesday, Sep 28, 2016



Lowell Anthony, MD, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses the various subtleties in defining the pathology of neuroendocrine tumors (NETs).

In many ways, the vocabulary used to define these tumors is extremely important, says Anthony. For example, a grade 1 NET could be benign or malignant. However, a poorly differentiated or undifferentiated tumor implies a carcinoma, which behaves very differently from a well-differentiated NET and requires more aggressive therapy.

Oncologists then face a bit of a conundrum in classifying the disease as either a tumor or a carcinoma, Anthony explains, which makes treating patients more complex. Patients may receive either too little or too aggressive treatment as a result.


Lowell Anthony, MD, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses the various subtleties in defining the pathology of neuroendocrine tumors (NETs).

In many ways, the vocabulary used to define these tumors is extremely important, says Anthony. For example, a grade 1 NET could be benign or malignant. However, a poorly differentiated or undifferentiated tumor implies a carcinoma, which behaves very differently from a well-differentiated NET and requires more aggressive therapy.

Oncologists then face a bit of a conundrum in classifying the disease as either a tumor or a carcinoma, Anthony explains, which makes treating patients more complex. Patients may receive either too little or too aggressive treatment as a result.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x